

## Macular Degeneration Guideline Committee – development

**Date:** 25/02/2016

**Location:** NICE offices, London

**Minutes:** Final

<b>Committee members present:</b>		
Waqar Shah (Chair)		Present for all items
Katy Barnard (KB)		Present for all items
Andy Charley (AC)		Present for all items
Cathie Burke (CB)		Joined during item 1
Jennifer Evans (JE)		Present for all items
Alexander Foss (AF)		Present for all items
Carol McCletchie (CM)		Present for all items
Ellen Rule (ER)		Present for all items
Elizabeth Wick (EW)		Present for all items
Mary-Ann Sherratt (MAS)		Joined partway through item 5
Cathy Yelf (CY)		Present for all items

<b>In attendance:</b>		
Stephen Duffield (SD)	ICG – Technical Analyst	Present for all items
Chris Gibbons (CG)	ICG – Technical Analyst (HE)	Present for all items
Vonda Murray (VM)	ICG – Project Manager	Present for all items
Dave Nicholls (DN)	NICE – Information Specialist	Present for all items
Gabriel Rogers (GR)	ICG – Technical Advisor	Present for all items

## Macular Degeneration Guideline Committee 4 minutes

	(HE)	
Joshua Pink	ICG – Technical Advisor	Present for all items

### Observers:

Rosa Domingues	NICE – Technical Analyst
Judith Hughes	PhD student

### Apologies:

Anne Louise Clayton (A-LC)	NICE – Medicine Senior Editor
Mary Freeman (MF)	Committee member
Sue Ellerby (SE)	ICG – Clinical Advisor
Caroline Keir (CK)	NICE – Guideline Commissioning Manager

## 1. Introductions, apologies, minutes, DOI and objectives for the meeting

The Chair welcomed the Committee members, attendees and observers to the fifth meeting on age-related macular degeneration (AMD). The committee members, attendees and observers introduced themselves.

Apologies were noted, as recorded above.

The Chair invited each attendee to declare any new conflicts since the previous meeting. The following conflicts were noted;

Attendee	Declaration	Action
Cathie Burke	Hosted a Macular Degeneration Awareness Day. Refreshments	Declare & participate

**Macular Degeneration Guideline Committee 4 minutes**

	provided by Bayer.	
Carol McCletchie	Attended a Macular Degeneration Awareness Day. Refreshments provided by Bayer.	Declare & participate
Alexander Foss	British Journal of Ophthalmology has accepted for publication an article on changes in intraocular pressure in study and fellow eyes in the Ivan trial	Declare & participate
Alexander Foss	Speaker at Royal College of GP's (02.02.16), study day on age related macular degeneration to GPs, no payment received	Declare & participate

It was agreed that all committee members were eligible to attend the committee meeting and contribute to the discussions and drafting of any recommendations.

The Chair updated the committee that a further Ophthalmologist had been recruited, and that they hope to attend GComm 7.

The minutes were reviewed from GComm 4; 13/01/2016. The minutes were agreed to be an accurate record.

The Chair provided a brief overview and objectives of the day highlighting the information that would be discussed.

## **2. Macular Degeneration late AMD**

AF presented key aspects of the physiology of AMD, answering questions from the committee. The Chair thanked AF for this presentation.

## **3. RQ6 What effective classification tool should be used to inform people with AMD? (part 2)**

SD presented evidence regarding the sub-classification of neovascular disease (RQ4: What tools are useful for triage, diagnosis, informing treatment and determining management in people with suspected AMD?)

The Committee discussed the evidence and recommendations were made.

**Action – VM to prepare a summary of the agreed terms for the classification of AMD**

## **4. RQ8 What is the effectiveness of psychological therapies for AMD?**

SD recapped the key elements of the search protocol, and presented the evidence of the effectiveness of psychological therapies for AMD. 9 papers were included. The committee made a recommendation around psychological therapies for AMD patients, and a research recommendation.

## 5. Protocols

Protocols for the following review questions were agreed:

RQ5. How do different organisational models and referral pathways for triage and diagnosis influence outcomes for people with suspected AMD (for example correct diagnosis, errors in diagnosis, delays in diagnosis, process outcomes)?

RQ9. What is the effectiveness of support strategies for people with visual impairment and AMD (for example reablement services and strategies for optimising existing visual performance)?

RQ11. What are the indicators for treatment failing and switching?

RQ13. What is the effectiveness of adjunctive therapies for the treatment of neovascular AMD?

RQ14. What factors indicate that treatment for neovascular AMD should be stopped?

## 6. AOB: Resource impact guidance

JP provided an overview of the document that had been sent to the committee 'Resource Impact in guidelines'.

## 7. Next steps

The Chair thanked the committee for their time and contribution to the meeting. The venue, date and time of the next meeting was confirmed.

**Macular Degeneration Guideline Committee 4 minutes**

**Date of next meeting:** Wednesday 6<sup>th</sup> April 2016

**Location of next meeting:** NICE offices, Manchester